Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial. The treatment combination of Pomalyst ...

The approval follows results from the RETRIEVE trial, conducted in patients who had previously responded to Velcade but had relapsed. The Takeda Oncology Company with its parent company, Takeda ...

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial. Velcade (bortezomib), Rituxan ...

(Reuters) - Takeda Pharmaceutical Co's Velcade reduced the risk of death by 31 percent when used in combination with standard medicines in previously untreated multiple myeloma patients, according to ...